Neurocrine Biosciences,NASDAQ: NBIX) is a biotechnology company headquartered in San Diego, California, focused on developing treatments for neurological and psychiatric disorders. The company has established itself as a leader in addressing unmet needs in movement disorders, particularly Parkinson's disease and Huntington's disease[1]. Founded in 1992, Neurocrine has successfully brought multiple CNS drugs to market, including Ingrezza (valbenazine) for tardive dyskinesia and Huntington's disease chorea, and Orthodopa (opicapide) for Parkinson's disease OFF periods.
Beyond its commercial portfolio, Neurocrine has entered the gene therapy space through a partnership with Roche on an AAV gene therapy program for Dravet syndrome targeting the SCN1A gene[2].
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| Ingrezza (valbenazine) | VMAT2 inhibitor | Tardive Dyskinesia | Approved | Commercial |
| Ingrezza (valbenazine) | VMAT2 inhibitor | Huntington's Disease chorea | Approved | Commercial |
| Orthodopa (opicapide) | COMT inhibitor | Parkinson's OFF periods | Approved | Commercial |
| CRENE (NB-188) | VMAT2 inhibitor (alternate formulation) | Tardive dyskinesia | Phase 1 | Active |
| NBI-1065846 | KCNQ2/3 channel opener | Focal onset seizures | Phase 1 | Active (Roche partnership) |
| SCN1A AAV (NB-XXXXX) | Gene replacement | Dravet syndrome | Preclinical | IND-enabling (Roche partnership) |
| NBI-817 | AADC gene therapy | Parkinson's Disease | Preclinical | Research |
| NBI-921 | Norepinephrine modulator | Parkinson's Disease | Discovery | Research |
Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (2017) and chorea in Huntington's disease (2023)[3]. It is one of the fastest-growing CNS drugs in the United States.
Orthodopa is a COMT inhibitor approved for Parkinson's disease OFF periods (2023), delivered as a continuous subcutaneous infusion[4].
Neurocrine entered a collaboration with Roche in the neuroscience gene therapy space, focusing on rare genetic epilepsies with high unmet need. The partnership targets Dravet syndrome — caused by loss-of-function variants in the SCN1A gene — using an AAV-delivered gene therapy approach[2:1].
The SCN1A gene therapy program represents Neurocrine's entry into the genetic medicine space:
The program competes in the Dravet gene therapy landscape alongside:
| Company | Approach | Stage |
|---|---|---|
| Stoke Therapeutics | ASO (STK-001) | Phase 2 (FDA BTD) |
| Encoded Therapeutics | AAV CRISPRa (ETX101) | Phase 1 |
| Roche/Neurocrine | AAV gene replacement | IND-enabling |
The AAV gene replacement approach differs from both the ASO (repeat dosing, non-viral) and CRISPRa (transcriptional activation) strategies. Like ETX101, an AAV approach would provide potentially durable, single-dose treatment — but with expression of the full SCN1A gene rather than CRISPR-mediated upregulation.
NBI-817 is an AAV-based gene therapy approach for Parkinson's disease designed to restore dopamine synthesis through delivery of the aromatic L-amino acid decarboxylase (AADC) gene directly to the striatum[5].
NBI-921 is a novel norepinephrine modulator in discovery research for Parkinson's disease, targeting the noradrenergic system which plays important roles in motor control and non-motor symptoms including cognitive dysfunction, depression, and autonomic symptoms[6].
A program targeting KCNQ2/KCNQ3 potassium channels (the M-current) for focal onset seizures, in partnership with Roche. This is distinct from the SCN1A Dravet program and leverages Neurocrine's expertise in ion channel modulation for epilepsy.
| Partner | Focus Area | Programs |
|---|---|---|
| Roche | Gene therapy | SCN1A AAV (Dravet), KCNQ2/3 opener |
| Voyager Therapeutics | Gene therapy | VY-AADC, NBI-817 (AADC for PD) |
| Teva Pharmaceutical | CNS development | Various |
| Metric | Value |
|---|---|
| Exchange | NASDAQ |
| Ticker | NBIX |
| Market Cap | ~$8-12B |
| Revenue (2025) | ~$1.5-1.8B (Ingrezza + Orthodopa) |
| Employees | ~1,200-1,500 |
| Cash Position | ~$1.2B |
| R&D Budget | ~$500M annually |
| Strengths | Challenges |
|---|---|
| Profitable commercial products (Ingrezza, Orthodopa) | Limited gene therapy experience |
| Established CNS commercial infrastructure | SCN1A program is early-stage |
| Roche partnership provides resources and expertise | Faces established competitors (Stoke, Encoded) |
| Strong cash position and profitability | AAV manufacturing is capital-intensive |
| Ion channel expertise (KCNQ2/3 opener) | Dravet market is small and competitive |
Neurocrine Biosciences Corporate Presentation Q1 2025. 2025. ↩︎
AADC Gene Therapy for Parkinson's Disease. Molecular Therapy. 2021. ↩︎
Norepinephrine in Parkinson's Disease. Nature Reviews Neurology. 2020. ↩︎